Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2020 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Other Non-Current Liabilities of $367000.0 for Q1 2026, up 270.71% year-over-year from $99000.0 in Q1 2025, and up 19.16% quarter-over-quarter from $308000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Other Non-Current Liabilities for 7 consecutive years, with $367000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 270.71% year-over-year to $367000.0; the TTM figure through Mar 2026 stood at $367000.0 (up 270.71% YoY), while the FY2025 annual figure was $308000.0, up 670.0% from the prior year.
- Other Non-Current Liabilities improved to $367000.0 in Q1 2026 per OBIO's latest filing, from $308000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $624000.0 in Q1 2022 and bottomed at $40000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $254454.5 across 5 years, with a median of $248000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 69.13% — and 2025, when it jumped 670.0%.
- Orchestra BioMed Holdings' Other Non-Current Liabilities stood at $196000.0 in 2022, then jumped by 35.71% to $266000.0 in 2023, then sank by 84.96% to $40000.0 in 2024, then surged by 670.0% to $308000.0 in 2025, then advanced by 19.16% to $367000.0 in 2026.
- Business Quant data shows OBIO's Other Non-Current Liabilities at $367000.0 in Q1 2026, $308000.0 in Q4 2025, and $248000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.46 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 248,000.00 |
| Jun 30, 2025 | 189,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Sep 30, 2023 | 266,000.00 |
| Jun 30, 2023 | 213,000.00 |
| Mar 31, 2023 | 2.37 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Mar 31, 2022 | 624,000.00 |
| Dec 31, 2021 | 635,000.00 |
| Dec 31, 2020 | 5.72 Mn |